Stockscreener 앱 받기
6.76
0.44%
-0.03
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr
Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat
What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Free Daily Top Performing Stock Insights - Newser
How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser
Published on: 2025-08-08 22:45:59 - Newser
What institutional flow reveals about Amicus Therapeutics Inc.Predictive Model for Intraday Swing Forecast - Newser
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com
Assetmark Inc. Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada
What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News
When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News
What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceMaximize your portfolio’s growth with expert tips - Jammu Links News
How does Amicus Therapeutics Inc. compare to its industry peersExceptional market performance - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stock outlookIntraday Price Forecast Using Volume Models - Newser
Should I hold or sell Amicus Therapeutics Inc. stock in 2025Unlock exclusive stock market insights - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is it the right time to buy Amicus Therapeutics Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Amicus Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mesirow Financial Investment Management Inc. Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics' Q2 Performance: A Glimpse into Rare Disease Growth and Strategic Risks - AInvest
Amicus Therapeutics Surpasses $1B Target Revenues with DMX-200 License Agreement - AInvest
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
FOLD Q2 Earnings Miss Mark, Revenues Beat On Higher Product Sales - Barchart.com
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript - Insider Monkey
What are analysts’ price targets for Amicus Therapeutics Inc. in the next 12 monthsDaily Trading Picks With High Returns - Jammu Links News
Envestnet Asset Management Inc. Has $1.52 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances - TipRanks
Amicus Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Amicus Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Drops 55.6% - AInvest
Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT - Insider Monkey
0.24%
3.39%
자본화:
|
볼륨(24시간):